Reading INDP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INDP free→Reading INDP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INDP free→QuarterlyIQ Insights · INDP
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Director, Chief Operating Officer — Mr. David E. Lazar, Mr. Avraham Ben-Tzvi, Mr. Walt A. Linscott, Esq.: Multiple senior executives and directors resigned from their positions.
Results of Operations and Financial Condition. On May 15, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) issued a press release (the “ Press Release ”) announcing its financial results for the quarter ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Press Release contains certain business updates and forward-looking statements regarding the Company’s expectations, plans and prospects. The information in this Current Re…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Directors On April 17, 2026, the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”) appointed Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors of the Board, effective April 22, 2026. Tim Ruan, 40, is a seasoned financial executive with extensive experience in capital markets, invest…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Directors On April 17, 2026, the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”) appointed Mr. Tim Ruan and Dr. Yi Zhang as independent directors of the Board, effective April 22, 2026. Tim Ruan, 40, is a seasoned financial executive with extensive experience in capital markets, investment banking,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Officer Nir Sassi resigned as Chief Financial Officer on April 1, 2026. Mr. Sassi’s resignation is not based on any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Appointment of Director and Officer On March 31, 2026, the Board of Directors appointed Qinglai Lu as a member of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Directors and Officers Jeffrey A. Meckler, Roger J. Pomerantz, Anthony J. Maddaluna, and William B. Hayes (together, the “Resigning Directors”) resigned on March 18, 2026. Mr. Meckler also resigned as co-Chief Executive Officer on March 18, 2026. David Lazar resigned as co-Chief Executive Officer on March 18, 2026, but remains on the…
of the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “Company”) on December 23, 2025, on December 22, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he purchased from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series AAA Convertible Preferred Stock (the “Series AAA Preferred Stock” and, together with the Serie…
Changes in Control of Registrant. As described in
Material Modification to Rights of Security Holders. As described below under
Changes in Control of Registrant As described below under
Unregistered Sales of Equity Securities. The information under
Entry into a Material Definitive Agreement. On February 11, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into warrant repricing agreements (the “Repricing Agreements”) with certain holders (the “Executing Holders”) of warrants to purchase an aggregate of 913,638 shares of common stock of the Company that were originally issued in financing rounds during 2024 and 2025 at exercise prices ranging from $8.30 to $47.60 (the “Executing Warrants”). Pursuant to the Repricing Agreements,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported on December 22, 2025, in connection with the transactions contemplated by the securities purchase agreement with investor David E. Lazar, Indaptus Therapeutics, Inc. (the “Company”) entered into employment modification agreements with, among others, Jeffrey A. Meckler, Co-Chief Executive Officer and Michael J. Newman, Ph.D.,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 29, 2025, Michael Newman, Mark Gilbert, and Anthony Maddaluna, members of the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”), each notified the Company of its resignation from the Board effective upon the approval of David Lazar’s nominees at the Company’s next stockholders’ meeting. The resignations wer…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Directors Mr. Robert E. Martell and Ms. Hila Karah (together, the “Resigning Directors”) resigned on December 22, 2025 and December 23, 2025, respectively, following approval of the offering. The resignation of each of the Resigning Directors is not based on any disagreement with the Company on any matter relating to the Company’s op…
Unregistered Sales of Equity Securities. The disclosure required by this Item and included in
Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 22, 2025, Indaptus, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he agreed to purchase from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series AAA Convertible Preferred Stock (the “Series AAA Preferred Stock” and, together with the Series AA Pr…
Material Modifications to Rights of Security Holders. The disclosure required by this Item and included in
Results of Operations and Financial Condition. On November 12, 2025, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securiti…
Results of Operations and Financial Condition. On August 13, 2025, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exch…
Unregistered Sales of Equity Securities. As previously reported on its Current Reports on Form 8-K filed on June 13, 2025 and July 1, 2025, Indaptus Therapeutics, Inc. (the “Company”) completed a private placement (the “Private Placement”) of convertible promissory notes (the “Notes”) and warrants (the “Warrants”) to certain accredited investors (the “Purchasers”) in two closings on June 12, 2025 and June 30, 2025, for total gross proceeds of approximately $5.7 million, before deducting the p…
Material Modification to Rights of Security Holders. To the extent required by
in its entirety. Based in part upon the representations of the Purchasers in the Purchase Agreements and Paulson in the PAA, the offering and sale of the Notes, Pre-Funded Warrants, Warrants and Placement Agent Warrants will be exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506(c) of Regulation D promulgated under the Securities Act. The issuances and sales of the Notes, Pre-Funded Warrants, Warrants, Placement Agen…
Entry into a Material Definitive Agreement. On June 12, 2025, Indaptus Therapeutics, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain accredited investors (the “Purchasers”) for the offering in a private placement of convertible promissory notes in the aggregate principal amount of $2.3 million (the “Notes”) and warrants (the “Warrants”) to purchase shares of common stock, par value $0.01 per share (“Common Stock”). The closing of priva…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The description of the Notes contained in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.